Compassionate use trial offers AML patients continued access to experimental oral chemo
NCT ID NCT06572982
First seen Jan 19, 2026 · Last updated May 25, 2026 · Updated 23 times
Summary
This study gives a small group of adults with acute myeloid leukemia (AML) continued access to an oral form of the chemotherapy drug azacitidine. All 20 participants had already completed a previous bioequivalence study of the same tablet. The main goal is to track any side effects and see how safe the drug is when used longer-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sheikh Shakhbout Medical City
Abu Dhabi, United Arab Emirates
Conditions
Explore the condition pages connected to this study.